A

    Abivax SA American Depositary Shares (ABVX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $111.73
    -1.62 (-1.43%)

    Market Cap: $9.75B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(6/12)
    Avg Surprise
    -10.28%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Jun 30, 2026
    EPS Consensus$-0.91
    Range$-1.42 - $-0.56
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.74+18.7%
    60d ago$-0.74+18.3%
    30d ago$-0.65+27.7%
    7d ago$-0.91-0.1%
    Current$-0.91
    Revenue Consensus
    $819070
    Range$0 - $2M
    5 analysts
    Period ending Sep 30, 2026
    EPS Consensus$-0.67
    Range$-0.88 - $-0.48
    3 analysts
    EPS Revisions
    1
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-0.71-5.1%
    60d ago$-0.71-5.6%
    30d ago$-0.60+11.0%
    7d ago$-0.69-2.9%
    Current$-0.67
    Revenue Consensus
    $817300
    Range$0 - $2M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.20---
    Sep 26EST
    		-$-0.67---
    Jun 26EST
    		-$-0.91---
    Mar 26
    Reported May 22
    		$-0.71$-0.81+12.35%Beat+25.3%
    Dec 25
    Reported Mar 23
    		$-1.18$-1.04-13.46%Miss-44.9%
    Sep 25
    Reported Dec 15
    		$-2.47$-0.79-212.66%Miss-243.1%
    Jun 25
    Reported Sep 8
    		$-0.89$-0.95+6.32%Beat+11.9%
    Mar 25
    Reported Jun 2
    		$-0.95$-0.76-25.00%Miss-20.2%
    Dec 24
    Reported Mar 24
    		$-0.81$-1.29+36.88%Beat-
    Sep 24
    Reported Nov 7
    		$-0.72$-0.79+8.86%Beat-12.5%
    Jun 24
    Reported Sep 9
    		$-1.01$-0.97-4.12%Miss-40.3%
    Mar 24
    Reported Apr 2
    		$-0.79$-0.60-31.72%Miss+59.4%
    Dec 23
    Reported Feb 6
    		$0.00N/A+100.00%Beat+100.0%
    Sep 23
    Reported Nov 29
    		$-0.64$-0.64+0.00%Beat+61.9%
    Jun 23
    Reported Sep 21
    		$-0.72$0.00N/AMiss+46.2%
    Dec 22
    Reported Dec 31
    		$-1.95$-1.93-0.81%Miss-2.6%
    Jun 22
    Reported Jun 30
    		$-1.84N/AN/ABeat-29.7%
    Dec 21
    Reported Dec 31
    		$-1.68N/AN/ABeat-9.5%
    Jun 21
    Reported Jun 30
    		$-1.34N/AN/ABeat+14.9%
    Dec 20
    Reported Dec 31
    		$-1.90N/AN/ABeat-93.1%
    Jun 20
    Reported Jun 30
    		$-1.42N/AN/ABeat-68.7%
    Dec 19
    Reported Dec 31
    		$-1.53N/AN/ABeat-133.9%
    Jun 19
    Reported Jun 30
    		$-1.57N/AN/ABeat-141.2%
    Dec 18
    Reported Dec 31
    		$-0.98N/AN/ABeat-52.3%
    Jun 18
    Reported Jun 30
    		$-0.84N/AN/ABeat-
    Dec 17
    Reported Dec 31
    		$-0.66N/AN/ABeat-
    Jun 17
    Reported Jun 30
    		$-0.65N/AN/ABeat-
    Dec 16
    Reported Dec 31
    		$-0.64N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-21.28EV/EBITDA-12.66x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-4184.00%
    ROE-157.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio8.25xQuick Ratio8.25x
    Trading Statistics
    Beta-0.23Avg Volume847.48K
    52-Week High$148.8352-Week Low$69.81

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$116.26
    SMA 20$120.76
    SMA 50$123.78
    SMA 200$119.28
    EMA 10$116.21
    EMA 20$119.17
    EMA 50$120.91
    EMA 200$110.20

    MACD

    Line: -3.19Signal: -2.24Hist: -0.95

    ADX

    ADX: 17.3+DI: 17.3-DI: 30.3

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down100.0
    PSAR$124.32

    Bollinger Bands

    Upper Band$132.06
    Lower Band$109.45
    %B Position1873%(Upper)
    Band Width0.10

    RSI (14-Day)

    Neutral
    35.5

    Momentum Oscillators

    Stoch %K5.9
    Stoch %D10.5
    Williams %R-97.8
    ROC (10d)-7.5%
    Momentum-9.00
    CCI (20d)-123.6
    MFI (14d)20.0

    Volatility Measures

    ATR (14d)$4.39(3.9%)
    StdDev (20d)5.65
    Hist Vol28.3%(Moderate)

    Volume Flow

    VWAP$112.47
    OBV38.3M
    AD Line-17.2M
    CMF (20d)-0.291

    Volume Metrics

    Avg Vol (20d)842.8K
    Vol Ratio1.3x
    VWMA (20d)$120.33

    Pivot Points

    R3$118.55
    R2$116.86
    R1$115.11
    Pivot Point$113.41
    S1$111.66
    S2$109.97
    S3$108.21

    Advanced Oscillators

    TSI-17.89
    Ultimate Osc31.9
    KST-91.56

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Jun 2023Mar 2023
    Total Revenue$0$-2,017,000$0$2.02M$0$7.40M$0$3.39M$0$2.33M$2.25MN/A
    Cost of RevenueN/A$1.03MN/AN/AN/AN/AN/AN/AN/A$378,000$329,000N/A
    Gross ProfitN/A$-3,046,690N/A$2.02MN/A$7.40MN/A$3.39MN/A$2.33M$2.25MN/A
    Operating Expenses$56.23M$199.56M$80.71M$46.50M$47.20M$47.20M$50.19M$35.33M$44.67M$92.08M$39.21MN/A
    R&D$49.54M$44.40M$55.42M$38.65M$39.30M$39.30M$43.29M$28.91M$35.74M$70.55M$32.62M$0
    SG&A$8.03M$27.68M$27.34M$8.91M$8.89M$8.72M$8.23M$11.70M$10.11M$15.63M$6.76M$0
    Operating Income$-56,229,000$-199,560,000$-80,712,000$-46,496,000$-47,200,000$-47,200,000$-50,189,000$-35,326,000$-44,671,000$-92,462,000$-39,535,000N/A
    Interest Income$769,000$807,000$3.53M$319,000$1.09M$1.64M$2.15M$2.45M$2.75M$0$0$0
    Interest Expense$2.54M$15.27M$4.21M$3.52M$4.54M$4.54M$4.74M$3.83M$2.42M$5.70M$14.70M$0
    Income Before Tax$-48,240,000$-281,840,000$-153,358,000$-48,414,000$-52,370,000$-52,370,000$-55,227,000$-38,770,000$-42,867,000$-98,045,000$-54,188,000$0
    Income Tax Expense$0$5.85M$0$0$0$0$0$0$0$-2,258,000$-2,235,000$0
    Net Income$-48,468,000$-287,688,000$-153,358,000$-48,414,000$-52,370,000$-52,370,000$-55,227,000$-38,771,000$-42,867,000$-95,787,000$-51,953,000N/A
    EBITDAN/A$-256,058,000N/A$-44,642,000N/A$-47,562,000N/A$-34,577,000N/A$-92,084,000$-39,206,000N/A
    EBITN/A$-256,879,000N/A$-44,893,000N/A$-47,835,000N/A$-34,942,000N/A$-92,462,000$-39,535,000$-18,640,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ABVX

    News

    NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier

    NetraMark Holdings Inc. has appointed Dr. Keith M. Fournier to its Board of Directors, leveraging his over 20 years of experience in global drug development and regulatory strategy from companies like AbbVie, Merck KGaA, AstraZeneca, and Abivax. This strategic addition aims to enhance NetraMark's engagement with drug developers and integrate deep pharmaceutical industry knowledge with its AI-powered precision analytics. Dr. Fournier's expertise will be crucial as NetraMark works to expand the application of its NetraAI technology in clinical trials to extract greater value from data and inform development strategies.

    The Manila Times•9/1/26•
    Somewhat-Bullish

    Abivax SA Sponsored ADR $ABVX Stock Holdings Increased by Seven Fleet Capital Management LP

    Seven Fleet Capital Management LP significantly increased its stake in Abivax SA Sponsored ADR (ABVX) by 158.6% in the second quarter, bringing its total holdings to 111,334 shares valued at $14.8 million. Institutional investors now collectively own 47.91% of Abivax stock. Despite a slight dip in share price on Thursday, analysts maintain a "Moderate Buy" consensus with an average price target of $156.50, indicating potential upside.

    MarketBeat•8/27/26•
    Bullish

    Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Recommendation of "Moderate Buy" by Brokerages

    Abivax SA Sponsored ADR (NASDAQ:ABVX) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month price target of $156.50, suggesting upside from its current $116.52 share price. Several analysts, including Morgan Stanley and BTIG Research, recently raised their price targets for the clinical-stage biotechnology company. Institutional investors hold a significant 47.91% stake in Abivax, with major increases in holdings from firms like UBS Group AG and Morgan Stanley.

    MarketBeat•8/27/26•
    Bullish

    Abivax SA Sponsored ADR $ABVX Shares Sold by Royal Bank of Canada

    Royal Bank of Canada reduced its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 51% in the first quarter, selling 15,744 shares and retaining 15,123 shares valued at approximately $1.68 million. Despite this reduction, institutional ownership remains significant at 47.91%, with other major firms like UBS, Morgan Stanley, and TCG Crossover Management increasing their positions. Abivax shares opened at $118.94, and analysts maintain a "Moderate Buy" consensus with an average price target of $156.50, following the company's strong performance in exceeding quarterly EPS and revenue expectations.

    MarketBeat•8/19/26•
    Somewhat-Bullish

    Understanding the Setup: (ABVX) and Scalable Risk

    This article provides an analysis of Abivax Sa (NASDAQ: ABVX), highlighting a weak near-term sentiment but potential long-term strength. It details specific AI-generated trading strategies including long, breakout, and short positions, along with support and resistance levels across different time horizons. The analysis suggests choppy conditions due to divergent sentiment.

    Stock Traders Daily•8/15/26•
    Somewhat-Bearish

    Frequently Asked Questions About ABVX

    Does ABVX pay dividends?
    Abivax SA American Depositary Shares (ABVX) does not currently pay a regular dividend.
    What is ABVX's market cap?
    Abivax SA American Depositary Shares (ABVX) has a market capitalization of $9.75B with a current stock price of $111.73.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In